The internist and scientist Jakob Nikolas Kather will fill the new Else Kröner Professorship for "Clinical Artificial Intelligence" at the EKFZ for Digital Health at Dresden University of Technology from June 1, 2022.
Dr. Jennifer Kirwan
Technologieplattform Metabolomik
Max-Delbrück-Centrum für Molekulare Medizin, Berlin
Charité-Stem Cell Facility, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum
Prof. Dr. rer nat. Gerald Willimsky, Institut für Immunologie - Charité-Universitätsmedizin Berlin und Deutsches Krebsforschungszentrum (DKFZ)
Dr. rer. nat. Felix Lorenz, Max-Delbrück-Centrum für Molekulare Medizin (MDC)
In this funding project, we will test a novel therapy option for acute myeloid leukemia (AML) treatment, in which tumor cell-specific antibodies as transport molecules are used to introduce siRNAs as an efficient therapeutic agent into the AML cells, where they are able to silence malignant modified gene products and thus inhibit leukemia growth.
Sepsis is an indication with an enormous unmet medical need. In western countries, more people die from sepsis than from the most common types of cancer combined. There is no effective and causative treatment available yet. To address this unmet medical need, we are developing alphaSEPT. alphaSEPT is a novel human immune signaling molecule developed in the laboratory of Prof. M. Feige. It has immunomodulatory properties that in the case of indications caused by an immune system out of control, are of central therapeutic importance.
Priv.-Doz. Dr. Johannes Fleckenstein
Arbeitsbereich Sportmedizin und Leistungsphysiologie
Institut für Sportwissenschaften
Goethe-Universität Frankfurt
About 6 million people in the EU including 800,000 people living in Germany suffer from epilepsy. Structural brain lesions like malformations of cortical development are a frequent cause of severe drug-resistant epilepsy. People with uncontrollable seizures face a lifetime of challenges including increased risk of injury and death. Epilepsy surgery provides a curative treatment option in some patients. Post-surgical outcome depends on the type of lesion and its complete resection.
Mortality in intensive care patients with liver failure, rhabdomyolysis or severe inflammation is high despite modern intensive care therapy. In these patients, the use of a special adsorber (=Cytosorb®) could be helpful in addition to standard therapy, although adsorption conduction and saturation kinetics for relevant substances in vivo are not yet known. This study investigates this by taking blood samples before and after the adsorber at different time points and determining various parameters.
Hepatocellular carcinoma (HCC) typically occurs in patients with chronic liver diseases and is the third leading cause of cancer-related deaths. Response rates to immunotherapies, such as checkpoint inhibitors, are still very low and likely depend on an inflamed tumor. In this project, we aim to generate a cancer vaccine that can induce inflammation of HCC tumors and therefore boost response to immunotherapies. We will test our vaccine in two animal models of HCC that represent the 2 most common etiologies of human liver cancer.
Type 2 diabetes mellitus not only leads to an increased risk of heart failure, but also to more severe course of the disease. Pathophysiological processes of how diabetes negatively affects the heart are not well understood. Alterations in cardiac energy metabolism induced by diabetes may contribute to a poorer prognosis in patients with heart failure. The aim of the current study is to characterize and compare the cardiac metabolism of heart failure patients with and without diabetes using metabolome analyses.
